Publication date: Jul 09, 2025
The use of immune checkpoint inhibitors (ICIs) is increasingly important in melanoma management. While ICIs are associated with immune-related adverse events (irAEs), little is known about skeleton irAEs and they are felt to be poorly described. We conducted a real-life, retrospective cohort study to monitor bone mineral density (BMD) evolution over 2 years using routine Computed Tomography (CT) in melanoma patients treated with ICIs and to identify associated factors. This single-center study included 165 patients (mean age: 65 years; 44. 2% women) treated with ICIs between 2014 and 2023. BMD was measured at baseline (T0), 1 year (T1), and 2 years (T2) on L1 vertebrae. Vertebral fractures were assessed on sagittal slices. Paired t-tests compared BMD values at the different time points, and we analyzed risk factors for BMD changes with regression models. BMD significantly decreased over 2 years (mean difference: 14. 02 Hounsfield Units (HU), 95% CI 10. 31-17. 74, p
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | osteoporosis |